Last reviewed · How we verify
Advantan (METHYLPREDNISOLONE ACEPONATE)
Advantan (generic name: METHYLPREDNISOLONE ACEPONATE) is a Corticosteroid drug. It is currently in Phase 2 development.
Advantan works by binding to glucocorticoid receptors in the body, which then suppresses the production of inflammatory chemicals.
Advantan (METHYLPREDNISOLONE ACEPONATE) is a corticosteroid medication developed by Schering-Plough, currently owned by Merck & Co. It is a small molecule that works by suppressing the immune system to reduce inflammation and swelling. Advantan is used to treat various skin conditions, including eczema and atopic dermatitis. The commercial status of Advantan is patented, and its safety considerations include potential side effects such as skin thinning and increased risk of infections. As a corticosteroid, Advantan should be used under medical supervision to minimize risks.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | METHYLPREDNISOLONE ACEPONATE |
|---|---|
| Drug class | Corticosteroid |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
Imagine your immune system is like a fire alarm that goes off when it senses something wrong. Advantan helps turn down the volume on the fire alarm, reducing the inflammation and swelling that can cause discomfort and pain. This allows the skin to heal and recover more quickly.
Approved indications
Common side effects
- Steroid withdrawal syndrome
- Euphoric mood
- Pelvic venous thrombosis
- Coagulation test abnormal
- Stupor
- Erythrodermic psoriasis
- Total bile acids increased
- Pulmonary embolism
- Disorientation
- Transaminases increased
Key clinical trials
- Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids (PHASE1)
- Efficacy and Safety Study of Advantan for Maintenance Treatment of Atopic Dermatitis (PHASE4)
- A Clinical Study of Adherence to Methylprednisolone Aceponate in Different Carriers (PHASE4)
- Prevention of Development of Transcutaneous Sensitization in Children With Atopic Dermatitis During Their First Year of Life (PHASE4)
- Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD) (PHASE2)
- Assess Itch Behavior in Nickel Sulphate Sensitized Volunteers (PHASE1)
- Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Advantan CI brief — competitive landscape report
- Advantan updates RSS · CI watch RSS
Frequently asked questions about Advantan
What is Advantan?
How does Advantan work?
What is the generic name of Advantan?
What drug class is Advantan in?
What development phase is Advantan in?
What are the side effects of Advantan?
Related
- Drug class: All Corticosteroid drugs
- Therapeutic area: All drugs in Immunology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing